BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30921622)

  • 1. High-grade ovarian serous carcinomas: Significant correlation of histologic patterns with IMP3 and E-Cadherin predicting disease recurrence and survival.
    Mohanty SK; Tiwari A; Singh C; Walsh C; Chuang F; Kim E; Singh K; Dadmanesh F
    Ann Diagn Pathol; 2019 Jun; 40():30-39. PubMed ID: 30921622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
    Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
    Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
    Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
    Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
    BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
    Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
    Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma.
    Shim HS; Yoon BS; Cho NH
    Hum Pathol; 2009 May; 40(5):693-8. PubMed ID: 19157508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.
    Deavers MT; Gershenson DM; Tortolero-Luna G; Malpica A; Lu KH; Silva EG
    Am J Surg Pathol; 2002 Sep; 26(9):1129-41. PubMed ID: 12218569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
    Huang LP; Yu YH; Sheng C; Wang SH
    Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression.
    Quattrocchi L; Green AR; Martin S; Durrant L; Deen S
    Virchows Arch; 2011 Jul; 459(1):21-9. PubMed ID: 21509572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
    Ahn G; Folkins AK; McKenney JK; Longacre TA
    Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of E-cadherin and cyclooxygenase enzymes in predicting different survival patterns of optimally cytoreduced serous ovarian cancer patients.
    Taşkin S; Dünder I; Erol E; Taşkin EA; Kiremitçi S; Öztuna D; Sertçelik A
    Asian Pac J Cancer Prev; 2012; 13(11):5715-9. PubMed ID: 23317244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
    Prat J; De Nictolis M
    Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.